Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126117331 | 12611733 | 1 | I | 20160516 | 20160801 | 20160801 | EXP | PL-ELI_LILLY_AND_COMPANY-PL201607013117 | ELI LILLY AND CO | 26.00 | YR | M | Y | 0.00000 | 20160801 | CN | PL | PL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126117331 | 12611733 | 1 | PS | OLANZAPINE. | OLANZAPINE | 1 | Oral | UNK, UNKNOWN | U | 20592 | TABLET | ||||||||
| 126117331 | 12611733 | 2 | SS | OLANZAPINE. | OLANZAPINE | 1 | Oral | 20 MG, QD | U | 20592 | 20 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126117331 | 12611733 | 1 | Psychotic disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126117331 | 12611733 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126117331 | 12611733 | Increased appetite | |
| 126117331 | 12611733 | Psychotic disorder | |
| 126117331 | 12611733 | Sedation | |
| 126117331 | 12611733 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |